These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 11372667)

  • 1. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
    Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
    Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Relationships to hormone replacement therapy.
    Lowe G; Woodward M; Vessey M; Rumley A; Gough P; Daly E
    Thromb Haemost; 2000 Apr; 83(4):530-5. PubMed ID: 10780311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET).
    Høibraaten E; Qvigstad E; Arnesen H; Larsen S; Wickstrøm E; Sandset PM
    Thromb Haemost; 2000 Dec; 84(6):961-7. PubMed ID: 11154141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
    Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of oral and transdermal estrogen replacement therapy on hemostatic variables associated with venous thrombosis: a randomized, placebo-controlled study in postmenopausal women.
    Post MS; Christella M; Thomassen LG; van der Mooren MJ; van Baal WM; Rosing J; Kenemans P; Stehouwer CD
    Arterioscler Thromb Vasc Biol; 2003 Jun; 23(6):1116-21. PubMed ID: 12730085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study.
    Collins P; Flather M; Lees B; Mister R; Proudler AJ; Stevenson JC;
    Eur Heart J; 2006 Sep; 27(17):2046-53. PubMed ID: 16899475
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hormone replacement therapy and hypercoagulability. Results from the Prospective Collaborative Danish Climacteric Study.
    Sidelmann JJ; Jespersen J; Andersen LF; Skouby SO;
    BJOG; 2003 Jun; 110(6):541-7. PubMed ID: 12798469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.
    Sgarabotto M; Baldini M; Dei Cas A; Manotti C; Luciana Barilli A; Rinaldi M; Benassi L; Bacchi Modena A
    Thromb Res; 2007; 119(1):85-91. PubMed ID: 16499954
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hemostatic effects of oral contraceptives in women who developed deep-vein thrombosis while using oral contraceptives.
    Bloemenkamp KW; Rosendaal FR; Helmerhorst FM; Koster T; Bertina RM; Vandenbroucke JP
    Thromb Haemost; 1998 Sep; 80(3):382-7. PubMed ID: 9759614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.
    Eilertsen AL; Qvigstad E; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2006 Oct; 55(3):278-87. PubMed ID: 16713143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term effects of estrogen, tamoxifen and raloxifene on hemostasis: a randomized-controlled study and review of the literature.
    Cosman F; Baz-Hecht M; Cushman M; Vardy MD; Cruz JD; Nieves JW; Zion M; Lindsay R
    Thromb Res; 2005; 116(1):1-13. PubMed ID: 15850603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women.
    Hemelaar M; Rosing J; Kenemans P; Thomassen MC; Braat DD; van der Mooren MJ
    Arterioscler Thromb Vasc Biol; 2006 Jul; 26(7):1660-6. PubMed ID: 16645152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
    Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
    Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Thrombophilic syndrome associated to phenotypic resistance to activated protein C in postmenopausal women].
    Caserta L; Caserta R; Torella M; Perricone F; Nesti E; Sessa M; Tagliaferri A; De Francesco F; De Lucia D; Panariello S
    Minerva Ginecol; 2004 Apr; 56(2):131-6. PubMed ID: 15258541
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate.
    Junge W; El-Samalouti V; Gerlinger C; Schaefers M
    Eur J Obstet Gynecol Reprod Biol; 2009 Dec; 147(2):195-200. PubMed ID: 19879683
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors and activation markers of the haemostatic system during hormone therapy: a comparative study of oral estradiol (2 mg)/ dydrogesterone and estradiol (2 mg)/ trimegestone.
    Norris LA; Brosnan J; Bonnar J; Conard J; Kluft C; Hellgren M
    Thromb Haemost; 2008 Aug; 100(2):253-60. PubMed ID: 18690345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII.
    Peverill RE; Teede HJ; Smolich JJ; Malan E; Kotsopoulos D; Tipping PG; McGrath BP
    Clin Sci (Lond); 2001 Jul; 101(1):93-9. PubMed ID: 11410120
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens.
    Fernandes EO; Moraes RS; Ferlin EL; Wender MC; Ribeiro JP
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S172-7. PubMed ID: 15683490
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hormone replacement therapy and acquired resistance to activated protein C: results of a randomized, double-blind, placebo-controlled trial.
    Høibraaten E; Mowinckel MC; de Ronde H; Bertina RM; Sandset PM
    Br J Haematol; 2001 Nov; 115(2):415-20. PubMed ID: 11703344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.